French software maker Dassault Systèmes is in talks to acquire U.S. life-sciences software company ArisGlobal for roughly $2 billion, a move aimed at strengthening its artificial-intelligence offering for the drug industry. The negotiations, which have not yet resulted in a signed agreement, would see Dassault purchase ArisGlobal from private-equity firm Nordic Capital, which took a majority stake in the business in 2019 (Reuters).
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.